By Rishika Sadam March 11 (Reuters) - India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns ...

India’s CDSCO warns pharma companies against promoting prescription weight-loss drugs like Semaglutide and Liraglutide to the public, urging ethical marketing and holistic obesity care.

The CDSCO said advertisements — including surrogate promotions — across print, electronic, digital or social media platforms ...

The Drugs Controller General of India (DCGI) has issued strict warning against promotional activities, including “awareness campaigns," that functions as a surrogate advertisement for ...

Ahead of the launch of the generic versions of the blockbuster GLP-1 drug semaglutide, the country’s apex drug regulator has issued an advisory warning that it should be sold only on prescription of a ...

In a determined effort to stem the tide of drug and substance abuse among students and youths in Abia, the Niger Delta Development Commission (NDDC), in strategic partnership with MARG Education ...

In a bold and strategic effort to combat the escalating menace of drug and substance abuse among youths, the Niger Delta Development Commission (NDDC) has intensified its intervention in Imo State ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for prescription-only drugs. The regulator in an advisory ...